Prestige Consumer Healthcare Hits 52-Week Low at USD 61.94

Prestige Consumer Healthcare, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 61.94 on September 15, 2025. This decline marks a significant point in the company's performance, as it has struggled to maintain momentum over the past year, with a reported performance of -4.14%, contrasting sharply with the S&P 500's gain of 17.67%.
The company's financial metrics reveal a mixed picture. Prestige Consumer Healthcare has a market capitalization of USD 3,511 million and a price-to-earnings (P/E) ratio of 20.00. However, it has not offered a dividend yield, and its debt-to-equity ratio stands at 0.46. The return on equity is reported at 11.94%, indicating a moderate level of profitability.

Recent quarterly results have shown net sales at their lowest, with figures of USD 249.53 million, operating profit at USD 79.42 million, and net profit at USD 47.47 million. The company's long-term growth has been modest, with net sales and operating profit growing at annual rates of 3.39% and 3.70%, respectively, over the last five years. As Prestige Consumer Healthcare navigates these challenges, its stock performance continues to reflect a cautious market sentiment.